on ABL DIAGNOSTICS (EPA:ABLD)
ABL Diagnostics is preparing for its General Assembly on June 30, 2026
On June 9, 2026, ABL Diagnostics, a company specializing in molecular biology tests, announced that its Ordinary and Extraordinary General Meeting will be held on June 30 in Paris. Shareholders will vote on the 2025 annual financial statements. The preliminary notice, including the agenda and voting procedures, was published on May 22, 2026, in the BALO (Bulletin des Annonces Légales Obligatoires).
Documents related to this meeting are available on the ABL Diagnostics website. The company, based in Woippy and listed on Euronext Paris, offers a range of solutions such as DNA genotyping and PCR. Its product portfolio includes HIV, SARS-CoV-2, and other diseases. ABL Diagnostics is also involved in a strategic agreement with CDL Pharma.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABL DIAGNOSTICS news